Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China’s National Medical Products Administration (NMPA) has approved...
Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply,...
Xellar Biosystems, a U.S.-based pioneer in “AI + organ-on-a-chip” technology, announced the successful completion of...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced an exclusive strategic partnership with TriNetX, Inc., granting Regeneron...
AstraZeneca plc (NYSE: AZN) announced positive top-line results from the EMERALD-3 Phase III clinical trial,...
RemeGen Ltd (HKG: 9995) announced it has received approval from China’s National Medical Products Administration...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced a strategic partnership with Sihuan...
Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive...
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received approval...
China’s National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide...
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced it has received approval from China’s National...
Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Amgen Inc. (NASDAQ: AMGN) announced a strategic collaboration...
Eli Lilly and Company (NYSE: LLY) announced it has received marketing approval from the US...
Eisai Co., Ltd. (TYO: 4523) announced the commercial launch of a 14-tablet specification of its...
Shanghai BDgene Technology Co., Ltd. announced the successful closing of a financing round securing hundreds...
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received clearance...
Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National...
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval...
Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing...
Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in...